Bunnik, the Netherlands, February 2, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, announced today the appointment of Bart Wuurman, M. Sc. as Chief Executive Officer. Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, UK, where he successfully implemented a restructuring and refinancing strategy.
